GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (BSP:REGN34) » Definitions » Cyclically Adjusted PB Ratio

Regeneron Pharmaceuticals (BSP:REGN34) Cyclically Adjusted PB Ratio : 8.85 (As of May. 01, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Regeneron Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-05-01), Regeneron Pharmaceuticals's current share price is R$75.05. Regeneron Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was R$8.48. Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 8.85.

The historical rank and industry rank for Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

BSP:REGN34' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 7.04   Med: 15.29   Max: 62.14
Current: 8.14

During the past years, Regeneron Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 62.14. The lowest was 7.04. And the median was 15.29.

BSP:REGN34's Cyclically Adjusted PB Ratio is ranked worse than
86.18% of 644 companies
in the Biotechnology industry
Industry Median: 1.74 vs BSP:REGN34: 8.14

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Regeneron Pharmaceuticals's adjusted book value per share data for the three months ended in Dec. 2023 was R$19.385. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is R$8.48 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Regeneron Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.38 10.52 9.95 8.39 8.03

Regeneron Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.39 8.89 7.30 7.88 8.03

Competitive Comparison of Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Regeneron Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=75.05/8.48
=8.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regeneron Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Regeneron Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=19.385/129.4194*129.4194
=19.385

Current CPI (Dec. 2023) = 129.4194.

Regeneron Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201403 0.850 99.695 1.103
201406 0.869 100.560 1.118
201409 0.973 100.428 1.254
201412 1.096 99.070 1.432
201503 1.507 99.621 1.958
201506 1.671 100.684 2.148
201509 2.061 100.392 2.657
201512 2.259 99.792 2.930
201603 2.210 100.470 2.847
201606 2.209 101.688 2.811
201609 2.309 101.861 2.934
201612 2.346 101.863 2.981
201703 2.387 102.862 3.003
201706 2.831 103.349 3.545
201709 2.942 104.136 3.656
201712 3.135 104.011 3.901
201803 3.328 105.290 4.091
201806 4.184 106.317 5.093
201809 4.979 106.507 6.050
201812 5.200 105.998 6.349
201903 5.517 107.251 6.657
201906 5.711 108.070 6.839
201909 6.573 108.329 7.853
201912 6.879 108.420 8.211
202003 8.807 108.902 10.466
202006 7.387 108.767 8.790
202009 8.547 109.815 10.073
202012 8.839 109.897 10.409
202103 10.548 111.754 12.215
202106 11.880 114.631 13.413
202109 13.994 115.734 15.649
202112 16.277 117.630 17.908
202203 15.083 121.301 16.092
202206 15.894 125.017 16.454
202209 17.221 125.227 17.798
202212 18.078 125.222 18.684
202303 18.593 127.348 18.895
202306 17.841 128.729 17.937
202309 18.838 129.860 18.774
202312 19.385 129.419 19.385

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regeneron Pharmaceuticals  (BSP:REGN34) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Regeneron Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Regeneron Pharmaceuticals (BSP:REGN34) Business Description

Traded in Other Exchanges
Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

Regeneron Pharmaceuticals (BSP:REGN34) Headlines

No Headlines